CDSimple™ CA 19-9 Colorimetric ELISA Kit

Name: CDSimple™ CA 19-9 Colorimetric ELISA Kit
SKU: DEIACL11
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

Serum

Species Reactivity

Human

Detection Method

sELISA

Intended Use

The Quantitative Determination of Cancer Antigen 19-9 (CA 19-9) Concentration in Human Serum by a Microplate Enzyme Immunoassay, Colorimetric

Contents of Kit

1. CA 19-9 Calibrators - 1 ml/vial - Six (6) vials of human serum based reference calibrators at concentrations of 0 (A), 10 (B), 50 (C), 100 (D), 250 (E) and 500 (F) U/ml. A preservative has been added. Store at 2-8 °C. Note: The standards, human serum based, were made using a > 99% pure affinity purified preparation of CA 19-9. The preparation was calibrated against Centocor CA 19-9 IRMA test.
2. CA 19-9 Biotin Reagent - 13 ml/vial One (1) vial of Anti-Human CA19-9 (MoAb)-Biotin reagent in a protein-stabilized matrix. A preservative has been added. Store at 2-8°C.
3. CA 19-9 Enzyme Reagent - 13 ml/vial - One (1) vial of Anti-Human CA19-9-HRP conjugate in a protein-stabilized matrix. A preservative has been added. Store at 2-8°C.
4. Streptavidin Plate - 96 wells - One 96-well microplate coated with streptavidin and packaged in an aluminum bag with a drying agent. Store at 2-8°C.
5. Wash Solution Concentrate - 20 ml/vial - One (1) vial containing a surfactant in buffered saline. A preservative has been added. Store at 2-8°C.
6. Substrate A - 7 ml/vial - One (1) vial containing tetramethylbenzidine (TMB) in acetate buffer. Store at 2-8°C. See "Reagent Preparation".
7. Substrate B - 7 ml/vial - One (1) vial containing hydrogen peroxide (H2O2) in acetate buffer. Store at 2-8°C. See "Reagent Preparation".
8. Stop Solution - 8 ml/vial - One (1) vial containing a strong acid (1N HCl). Store at 2-8°C.
9. Product Instructions

Note 1: Do not use reagents beyond the kit expiration date.
Note 2: Avoid extended exposure to heat and light. Opened reagents are stable for sixty (60) days when stored at 2-8°C. Kit and component stability are identified on the label.
Note 3: Above reagents are for a single 96-well microplate

Storage

The unopened kit can be stored at 2-8°C.

Sensitivity

1.0 U/ml

Citations

Have you cited DEIACL11 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

Impact of Borderline Resectability in Pancreatic Head Cancer on Patient Survival: Biology Matters According to the New International Consensus Criteria

ANNALS OF SURGICAL ONCOLOGY

Authors: Anger, Friedrich; Doering, Anna; van Dam, Jacob; Lock, Johan Friso; Klein, Ingo; Bittrich, Max; Germer, Christoph-Thomas; Wiegering, Armin; Kunzmann, Volker; van Eijck, Casper; Loeb, Stefan

Abstract

Background. International consensus criteria (ICC) have redefined borderline resectability for pancreatic ductal adenocarcinoma (PDAC) according to three dimensions: anatomical (BR-A), biological (BR-B), and conditional (BR-C). The present definition acknowledges that resectability is not just about the anatomic relationship between the tumour and vessels but that biological and conditional dimensions also are important. Methods. Patients' tumours were retrospectively defined borderline resectable according to ICC. The study cohort was grouped into either BR-A or BR-B and compared with patients considered primarily resectable (R). Differences in postoperative complications, pathological reports, overall (OS), and disease-free survival were assessed. Results. A total of 345 patients underwent resection for PDAC. By applying ICC in routine preoperative assessment, 30 patients were classified as stage BR-A and 62 patients as stage BR-B. In total, 253 patients were consideredR. The cohort did not contain BR-C patients. No differences in postoperative complications were detected. Median OS was significantly shorter in BR-A (15 months) and BR-B (12 months) compared withR(20 months) patients (BR-A vs.R:p = 0.09 and BR-B vs.R:p < 0.001). CA19-9, as the determining factor of BR-B patients, turned out to be an independent prognostic risk factor for OS. Conclusions. Preoperative staging defining surgical resectability in PDAC according to ICC is crucial for patient survival. Patients with PDAC BR-B should be considered for multimodal neoadjuvant therapy even if considered anatomically resectable.

Biliary Peritonitis due to a Ruptured Amebic Liver Abscess Mimicking a Periampullary Tumor and Liver Metastases with the Elevation of CA 19-9 and CA 125: A Case Report

GE PORTUGUESE JOURNAL OF GASTROENTEROLOGY

Authors: Marin-Leiva, Javiera; Jeri-Yabar, Antoine; Fernandez, Wendy Hernandez; Bello, Edwin Damian

Abstract

Introduction: An amebic liver abscess is the most common presentation of extraintestinal amebiasis. This condition is the result of a parasite infection caused by Entamoeba histolytica. Materials and Methods: We report a case of a 53-year-old male who presented with abdominal pain in the right upper quadrant, jaundice, and a 10-kg weight loss within a 1-month span. Results and Conclusion: A wide range of symptoms and findings in the imaging tests suggestive of neoplasia, elevated levels of CA 19-9 and CA 125, and the presentation of biliary peritonitis as a complication makes this case a challenge for its approach and management.